Observed cancers, O/E ratios, and 95% CIs
| Cancer type . | No. of observed cancers* . | O/E Ratio . | 95% CI . |
|---|---|---|---|
| Events with significant O/E ratios | |||
| All cancers | 18* | 5.4 | 3.2-8.6 |
| Colon (adenocarcinoma) | 3 | 36.2 | 7.5-105.8 |
| Bones (osteogenic) | 2 | 32.6 | 4.0-117.7 |
| Female genital† | 3 | 12.0 | 2.5-35.1 |
| AML‡ | 2 | 27.9 | 3.4-100.9 |
| MDS‡ | 4 | 287.0 | 77.2-734.7 |
| Events with nonsignificant O/E ratios | |||
| Oral cavity | 1 | 15.9 | 0.4-88.3 |
| Soft tissue sarcoma | 1 | 9.8 | 0.3-54.8 |
| Lung | 1 | 8.3 | 0.2-46.4 |
| Testis | 1 | 8.3 | 0.2-46.1 |
| Non-Hodgkin lymphoma | 1 | 5.7 | 0.1-31.7 |
| Melanoma | 1 | 4.5 | 0.1-25.3 |
| Breast | 2 | 4.1 | 0.5-14.9 |
| Cancer type . | No. of observed cancers* . | O/E Ratio . | 95% CI . |
|---|---|---|---|
| Events with significant O/E ratios | |||
| All cancers | 18* | 5.4 | 3.2-8.6 |
| Colon (adenocarcinoma) | 3 | 36.2 | 7.5-105.8 |
| Bones (osteogenic) | 2 | 32.6 | 4.0-117.7 |
| Female genital† | 3 | 12.0 | 2.5-35.1 |
| AML‡ | 2 | 27.9 | 3.4-100.9 |
| MDS‡ | 4 | 287.0 | 77.2-734.7 |
| Events with nonsignificant O/E ratios | |||
| Oral cavity | 1 | 15.9 | 0.4-88.3 |
| Soft tissue sarcoma | 1 | 9.8 | 0.3-54.8 |
| Lung | 1 | 8.3 | 0.2-46.4 |
| Testis | 1 | 8.3 | 0.2-46.1 |
| Non-Hodgkin lymphoma | 1 | 5.7 | 0.1-31.7 |
| Melanoma | 1 | 4.5 | 0.1-25.3 |
| Breast | 2 | 4.1 | 0.5-14.9 |
All data shown are significant at P < .05.
Eighteen cancers in 17 individuals. One person had breast cancer, colon cancer, and MDS at ages 43, 49, and 51 years.
Female genital included cervix, uterus, and vagina. Respective O/E ratios were 11.27 (0.29-62.78), 14.2 (0.36-79.14), and 270.81 (6.86-1508.83).
MDS is not included in the cancers. One patient had MDS followed by AML and is counted in both groups. A second patient is referred to above, with breast, colon, and MDS.